Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of dapirolizumab pegol added to standard of care in moderate to severe systemic lupus erythematosus
NL-OMON60824Phase 3Recruiting
- Sponsor
- UCB
- Start
- Sep 2026
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3 trial of dapirolizumab pegol in systemic lupus erythematosus (SLE) (2 arms), sponsored by UCB. Primary endpoint: BICLA response at Week 48. Started Sep 2026; status: recruiting.
02
Drugs
dapirolizumab pegol
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON60824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60824.